Arbutus Launches $230M Dutch Auction Tender at $5.00–$5.75/Share
ABUS sits 51% above its 52-week low of $3.44 on elevated volume (8.0× avg).
Summary
Arbutus Biopharma commenced its $230 million modified Dutch auction tender offer, pricing the buyback at $5.00–$5.75 per share with a September 29, 2026 expiration. The offer would retire 20–23% of outstanding shares, funded by the Moderna settlement cash.
Key Events · Financing and Capital Events · ABUS
-
$230M Dutch Auction Tender Commences
A modified Dutch auction tender offer has been launched to repurchase up to $230 million of common shares at $5.00–$5.75 per share, expiring September 29, 2026.
-
20–23% of Shares Could Be Retired
At the $5.00 minimum, up to 46,000,000 shares (23.2% of 198,105,743 outstanding) would be purchased; at the $5.75 maximum, up to 40,000,000 shares (20.2%).
-
Funded by Moderna Settlement Cash
The repurchase will be funded from available cash on hand, including the $178 million noncontingent payment received July 8, 2026 under the Moderna settlement agreement.
-
Roivant to Maintain 19.6% Stake
Roivant Sciences Ltd., holder of 38,847,462 shares (19.6%), intends to make a Proportionate Tender, preserving its ownership percentage while other shareholders tender.
Analysis · ABUS · Life Sciences
The terms of the $230 million modified Dutch auction tender offer are now final, with a price range of $5.00 to $5.75 per share and an expiration date of September 29, 2026. If fully subscribed, the offer would retire between 40 million and 46 million shares — roughly 20% to 23% of the 198.1 million shares outstanding — funded entirely from cash on hand, including the $178 million Moderna settlement payment received in July. The board is making no recommendation, but the structure is notable: Roivant, the 19.6% holder, will make a Proportionate Tender to maintain its stake, while directors and officers intend to tender up to 682,630 shares. For non-tendering shareholders, the buyback mechanically increases their ownership by 25% to 30% if fully subscribed. The offer is not conditioned on any minimum tender or financing, and the company has obtained exemptive relief from U.S. and Canadian regulators for the proportionate tender feature.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $5.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.44 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.